Instacart downgraded as competition tightening grip on online grocery
Director Brian Guan-Chyun Liu reported purchasing 1,515,151 shares of CG Oncology, Inc. (NASDAQ:CGON) common stock on September 11, 2025, at a price of $33.0, for a total transaction value of $49,999,983. The purchase comes as the stock trades near its 52-week high of $40.47, with analyst price targets ranging from $40 to $82. According to InvestingPro analysis, the stock’s RSI suggests it’s in overbought territory, though the company has shown strong returns over the past three months.Want deeper insights into insider trading patterns and 12+ additional ProTips? Explore the comprehensive CG Oncology Pro Research Report, available exclusively on InvestingPro.
In other recent news, CG Oncology has reported significant developments in its ongoing cancer treatment trials. The company announced updated data from its Phase 3 BOND-003 Cohort C study, which revealed a 41.8% complete response rate at 24 months for its bladder cancer treatment, cretostimogene. This data underscores the treatment’s durability, with 46 out of 110 patients maintaining a complete response, and 90% of those who responded at 12 months remaining disease-free at 24 months.
Additionally, H.C. Wainwright reiterated its Buy rating for CG Oncology, maintaining a price target of $75.00, citing impressive clinical data from the company’s bladder cancer treatment. Jones Trading also initiated coverage of CG Oncology with a Buy rating, setting a price target of $50.00. The focus of their analysis was on the development of cretostimogene grenadenorepvec for Non-Muscle Invasive Bladder Cancer in various treatment settings. Furthermore, there are insights regarding the pricing of Inlexzo, with third-party sources indicating a price of approximately $69,000 per dose, although Johnson & Johnson has not officially confirmed this.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.